Cargando…
COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office
BACKGROUND: Following the authorization and recommendations for use of the U.S. COVID-19 vaccines, the Centers for Disease Control and Prevention (CDC)’s Immunization Safety Office (ISO) responded to inquiries and questions from public health officials, healthcare providers, and the general public o...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208263/ https://www.ncbi.nlm.nih.gov/pubmed/37248099 http://dx.doi.org/10.1016/j.vaccine.2023.05.054 |
_version_ | 1785046631175946240 |
---|---|
author | Miller, Elaine R. Moro, Pedro L. Shimabukuro, Tom T. Carlock, Grace Davis, Shaeyla N. Freeborn, Emma M. Roberts, Amy L. Gee, Julianne Taylor, Allan W. Gallego, Ruth Suragh, Tiffany Su, John R. |
author_facet | Miller, Elaine R. Moro, Pedro L. Shimabukuro, Tom T. Carlock, Grace Davis, Shaeyla N. Freeborn, Emma M. Roberts, Amy L. Gee, Julianne Taylor, Allan W. Gallego, Ruth Suragh, Tiffany Su, John R. |
author_sort | Miller, Elaine R. |
collection | PubMed |
description | BACKGROUND: Following the authorization and recommendations for use of the U.S. COVID-19 vaccines, the Centers for Disease Control and Prevention (CDC)’s Immunization Safety Office (ISO) responded to inquiries and questions from public health officials, healthcare providers, and the general public on COVID-19 vaccine safety. METHODS: We describe COVID-19 vaccine safety inquiries, by topic, received and addressed by ISO from December 1, 2020–August 31, 2022. RESULTS: Of the 1978 COVID-19 vaccine-related inquiries received, 1655 specifically involved vaccine safety topics. The most frequently asked-about topics included deaths following vaccination, myocarditis, pregnancy, and reproductive health outcomes, understanding or interpreting data from the Vaccine Adverse Event Reporting System (VAERS), and thrombosis with thrombocytopenia syndrome. CONCLUSIONS: Inquiries about vaccine safety generally reflect issues that receive media attention. ISO will continue to monitor vaccine safety inquiries and provide accurate and timely information to healthcare providers, public health officials, and the general public. |
format | Online Article Text |
id | pubmed-10208263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-102082632023-05-25 COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office Miller, Elaine R. Moro, Pedro L. Shimabukuro, Tom T. Carlock, Grace Davis, Shaeyla N. Freeborn, Emma M. Roberts, Amy L. Gee, Julianne Taylor, Allan W. Gallego, Ruth Suragh, Tiffany Su, John R. Vaccine Short Communication BACKGROUND: Following the authorization and recommendations for use of the U.S. COVID-19 vaccines, the Centers for Disease Control and Prevention (CDC)’s Immunization Safety Office (ISO) responded to inquiries and questions from public health officials, healthcare providers, and the general public on COVID-19 vaccine safety. METHODS: We describe COVID-19 vaccine safety inquiries, by topic, received and addressed by ISO from December 1, 2020–August 31, 2022. RESULTS: Of the 1978 COVID-19 vaccine-related inquiries received, 1655 specifically involved vaccine safety topics. The most frequently asked-about topics included deaths following vaccination, myocarditis, pregnancy, and reproductive health outcomes, understanding or interpreting data from the Vaccine Adverse Event Reporting System (VAERS), and thrombosis with thrombocytopenia syndrome. CONCLUSIONS: Inquiries about vaccine safety generally reflect issues that receive media attention. ISO will continue to monitor vaccine safety inquiries and provide accurate and timely information to healthcare providers, public health officials, and the general public. Elsevier Science 2023-06-19 2023-05-24 /pmc/articles/PMC10208263/ /pubmed/37248099 http://dx.doi.org/10.1016/j.vaccine.2023.05.054 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Miller, Elaine R. Moro, Pedro L. Shimabukuro, Tom T. Carlock, Grace Davis, Shaeyla N. Freeborn, Emma M. Roberts, Amy L. Gee, Julianne Taylor, Allan W. Gallego, Ruth Suragh, Tiffany Su, John R. COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office |
title | COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office |
title_full | COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office |
title_fullStr | COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office |
title_full_unstemmed | COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office |
title_short | COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office |
title_sort | covid-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208263/ https://www.ncbi.nlm.nih.gov/pubmed/37248099 http://dx.doi.org/10.1016/j.vaccine.2023.05.054 |
work_keys_str_mv | AT millerelainer covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice AT moropedrol covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice AT shimabukurotomt covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice AT carlockgrace covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice AT davisshaeylan covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice AT freebornemmam covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice AT robertsamyl covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice AT geejulianne covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice AT taylorallanw covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice AT gallegoruth covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice AT suraghtiffany covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice AT sujohnr covid19vaccinesafetyinquiriestothecentersfordiseasecontrolandpreventionimmunizationsafetyoffice |